|
注册号: Registration number: |
ChiCTR2600124308 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-10 21:22:37 |
|
注册时间: Date of Registration: |
2026-05-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于IMB理论的多组分运动干预在骨质疏松合并衰弱患者术后康复中的应用效果研究 |
|
Public title: |
Research on the application effect of multi-component exercise intervention based on IMB theory in the postoperative rehabilitation of patients with osteoporosis complicated by frailty |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于IMB理论的多组分运动干预在骨质疏松合并衰弱患者术后康复中的应用效果研究 |
|
Scientific title: |
Research on the application effect of multi-component exercise intervention based on IMB theory in the postoperative rehabilitation of patients with osteoporosis complicated by frailty |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
肖鑫 |
研究负责人: |
肖鑫 |
|
Applicant: |
Xiao Xin |
Study leader: |
Xiao Xin |
|
申请注册联系人电话: Applicant telephone: |
+86 510 8535 0110 |
研究负责人电话:
Study leader's |
+86 510 8535 0110 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1726438334@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1726438334@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省无锡市清扬路299号 |
研究负责人通讯地址: |
江苏省无锡市清扬路299号 |
|
Applicant address: |
No. 299, Qingyang Road, Wuxi City, Jiangsu Province |
Study leader's address: |
No. 299, Qingyang Road, Wuxi City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
无锡市人民医院 |
||
|
Applicant's institution: |
Wuxi People's Hospital |
||
|
研究负责人所在单位: |
无锡市人民医院 |
||
|
Affiliation of the Leader: |
Wuxi People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY26096 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
无锡市人民医院科研伦理委员会 |
||
|
Name of the ethic committee: |
Research Ethics Committee of Wuxi People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-14 00:00:00 | ||
|
伦理委员会联系人: |
彭雁 |
||
|
Contact Name of the ethic committee: |
Peng Yan |
||
|
伦理委员会联系地址: |
江苏省无锡市清扬路299号 |
||
|
Contact Address of the ethic committee: |
No. 299, Qingyang Road, Wuxi City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 510 85350835 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
76489926@qq.com |
|
研究实施负责(组长)单位: |
无锡市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Wuxi people’s Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省无锡市清扬路299号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 299, Qingyang Road, Wuxi City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
研究疾病: |
骨质疏松合并衰弱 |
||||||||||||||||||||||
|
Target disease: |
Osteoporosis combined with weakness |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
骨质疏松症合并衰弱患者的术后康复治疗现状尚不理想,亟需加强患者康复意识、提升康复机构的专业水平,并完善康复治疗体系,以提供更高质量的术后康复服务,促进患者功能恢复。 |
||||||||||||||||||||||
|
Objectives of Study: |
The current status of postoperative rehabilitation in patients with osteoporosis combined with frailty is not ideal. It is urgent to strengthen the rehabilitation awareness of patients, improve the professional level of rehabilitation institutions, and improve the rehabilitation treatment system, so as to provide higher quality postoperative rehabilitation services and promote the functional recovery of patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.严重心肺功能不全; 2.恶性肿瘤; 3.急性感染; 4.认知障碍无法配合; 5.参与其他临床试验; 6.12 周内无法保证参与时间者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Severe cardiac and pulmonary dysfunction; 2. Malignant tumor; 3. Acute infection; 4. Cognitive impairment and inability to cooperate; 5. Participation in other clinical trials; 6. Those who cannot guarantee participation time within 12 weeks. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-11 00:00:00 至 To 2026-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由第三方人员使用计算机生成随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A random sequence is generated by a third-party person using a computer. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
对评估者隐藏分组 |
|
Blinding: |
Hide the groups from the evaluators |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |